🌍September 30, 2026·3h agoIndustryTier 1 · Company source

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

Publisher

Tiziana Life Sciences

Global

This page provides publisher metadata, and related coverage to support discovery before sending readers to the publisher's original article.

Read original

At a glance

Publisher: Tiziana Life Sciences
Region: 最新
Scope: Industry
Published: September 30, 2026

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on tizianalifesciences.com

Leave the platform to read the original full article on the publisher site.

Source: Tiziana Life Sciences

Scope: Industry

Evidence: Tier 1 · Company source

Open original article

Related coverage

More related coverage

WuXi Biologics/7h ago

Beyond Viscosity: Matching Impact of Injection Force Differences Between Drug Product and Placebo on Use Experience

Avacta Group/8h ago

Interim Results for the Six Months to June 30, 2026, and Business Update

AbbVie News/4h ago

AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026

Sumitomo Pharma/8h ago

Topline Results from the Final Analysis of the Phase 1 Study in Europe on a Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546)